5 Best Rated Penny Stocks to Buy According to Analysts

2. Precision BioSciences, Inc. (NASDAQ:DTIL)

Analyst Price Target: $7.75

Upside Potential: 1055.34%

Genome editing platform company Precision BioSciences, Inc. (NASDAQ:DTIL) shares were trading at around $0.67 as of July 13. According to TipRanks, Precision BioSciences, Inc. (NASDAQ:DTIL)’s average analyst price estimate is $7.75. This shows an upside potential of 1055% from the current levels.

In May, Precision BioSciences, Inc. (NASDAQ:DTIL)’s zercabtagene zapreleucel (azer-cel), an allogenic CD19 CAR T therapy for non-Hodgkin lymphoma (NHL) demonstrated strong results in a phase 1 trial.

A total of 9 hedge funds in Insider Monkey’s database of 943 hedge funds had stakes in Precision BioSciences, Inc. (NASDAQ:DTIL). The biggest stakeholder of Precision BioSciences, Inc. (NASDAQ:DTIL) during this period was Jeffrey Jay and David Kroin’s  Great Point Partners which owns a $6.1 million stake in the company.